Resveratrol supplement for Parkinson's disease
Part of Brain & nervous system clinical trials.
This study tests whether a supplement called resveratrol (found naturally in grapes and berries) can help slow or improve Parkinson's disease symptoms. You'll take resveratrol pills or a placebo while researchers monitor your memory, movement, and overall health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 55–85 and diagnosed with Parkinson's disease using standard diagnostic criteria
- Stable on Parkinson's medications (levodopa and/or dopamine agonists) for at least 4 weeks
- Score 18 or higher on the Montreal Cognitive Assessment (memory/thinking test)
- Hoehn & Yahr stage 2 or 3 (moderate mobility symptoms)
- Not taking anti-coagulants (blood thinners like Coumadin), other supplements, or enrolled in another study
- No psychiatric symptoms (like hallucinations or severe depression) or uncontrolled medical conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a supplement called NAD (a natural substance that helps cells produce energy) can improve symptoms in people with Parkinson's disease. You would take the supplement daily for several weeks, and researchers will check your movement, thinking, and overall well-being.
This study tests an investigational drug to see if it can help people with early Parkinson's disease. It may offer a new treatment option to manage symptoms.
This study tests whether a supplement called D-serine can slow the progression of Parkinson's disease. It is for people diagnosed within the last 5 years who have mild to moderate symptoms and are not yet dependent on a wheelchair.
This trial tests a new drug, PDR-001, to see if it can safely remove harmful proteins from the brain in people with early Parkinson's disease. It may help slow down the disease.
This trial tests an experimental oral drug called GT-02287 for people with early-stage Parkinson's disease. The study aims to see if the drug can slow progression by targeting a protein linked to Parkinson's, and participants must be willing to have genetic testing and a spinal tap to check for that protein marker.
This trial tests a supplement called tributyrin to see if it can help with thinking and memory problems in people with Parkinson's disease. You may be able to join if you have both Parkinson's and mild cognitive impairment or dementia.
Hear when a new Parkinson’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.